[
    [
        {
            "time": "2018-12-21",
            "original_text": "Novartis Enters Oversold Territory (NVS)",
            "features": {
                "keywords": [
                    "Novartis",
                    "Oversold",
                    "Territory"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-12-21",
            "original_text": "Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug",
            "features": {
                "keywords": [
                    "Gene",
                    "Therapy",
                    "Cost",
                    "Effective",
                    "Biogen"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-12-21",
            "original_text": "Pfizer and GlaxoSmithKlineâ€™s Joint Venture: What to Expect",
            "features": {
                "keywords": [
                    "Pfizer",
                    "GlaxoSmithKline",
                    "Joint",
                    "Venture"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-12-21",
            "original_text": "Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer",
            "features": {
                "keywords": [
                    "Novartis",
                    "Offers",
                    "Buy",
                    "French",
                    "Gene",
                    "Therapy",
                    "Manufacturer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-12-21",
            "original_text": "Pre-Market Most Active for Dec 21, 2018 : NVS, AFL, NBR, GNW, AMD, SQQQ, TQQQ, KBR, QQQ, FOXA, NIO, VOD",
            "features": {
                "keywords": [
                    "Pre-Market",
                    "Most",
                    "Active",
                    "NVS",
                    "AFL",
                    "NBR",
                    "GNW",
                    "AMD",
                    "SQQQ",
                    "TQQQ",
                    "KBR",
                    "QQQ",
                    "FOXA",
                    "NIO",
                    "VOD"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "diverse"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 10,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-12-21",
            "original_text": "U.S body says gene therapy may be more cost effective for spinal muscular atrophy",
            "features": {
                "keywords": [
                    "U.S",
                    "body",
                    "gene",
                    "therapy",
                    "cost",
                    "effective",
                    "spinal",
                    "muscular",
                    "atrophy"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]